
Quarterly ResultAug 6, 2026, 04:24 PM
Lyell Immunopharma Clinical Trials Advance; Q2 Net Loss $44.8M
AI Summary
Lyell Immunopharma reported a net loss of $44.8 million for the second quarter of 2026, an increase from $42.7 million in the same period last year, primarily due to higher R&D expenses. The company maintains a strong cash position of $228.0 million, providing a runway into Q3 2027. Significant clinical progress was highlighted for ronde-cel, with pivotal data expected mid-2027, and for LYL273, which showed improved safety data and an amended trial design for seamless expansion.
Key Highlights
- Reported Q2 2026 net loss of $44.8M, compared to $42.7M in Q2 2025.
- Research and development expenses increased to $39.5M in Q2 2026.
- Cash, cash equivalents, and marketable securities were $228.0M as of June 30, 2026.
- Cash runway is expected to extend into Q3 2027.
- Ronde-cel pivotal data expected mid-2027, with BLA submission in H2 2027.
- LYL273 safety data showed Grade ≥ 2 diarrhea/colitis reduced from 55% to 10%.
- LYL273 U.S. Phase 1 trial amended to a Phase 1/2 design for expansion.
Price Impact
More from LYEL
Quarterly ResultNov 4, 4:23 PM
Lyell Immunopharma Q3 Net Loss $45.5M; Raises $80M; Ronde-cel Data Positive
Quarterly ResultAug 6, 4:40 PM
Lyell Immunopharma Q2 Net Loss $(44.8)M; YTD Loss $(68.9)M; Raises $50M
Board MeetingJun 25, 8:01 AM
Lyell Immunopharma to Participate in H.C. Wainwright Virtual Conference